Home / Publication / Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

論文

Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

Author(s): Y. Mori, Hidefumi Kasai, A. Ose, M. Serada, M. Ishiguro, M. Shiraki, Y. Tanigawara

Year: 2018年2月8日

How Model-informed drug development rescue projects from a risky situation

事例紹介

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

論文

Powered by Translations.com GlobalLink Web Software

Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

How Model-informed drug development rescue projects from a risky situation

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

メルマガ登録

クイックアクセス

ソリューション

お問合せ

Modeling and Simulation of Bone Mineral Density in Japanese Osteoporosis Patients Treated with Zoledronic Acid Using Tartrate-resistant Acid Phosphatase 5b, a Bone Resorption Marker

How Model-informed drug development rescue projects from a risky situation​

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation